Core Viewpoint - China Resources Pharmaceutical announced the potential sale of approximately 17.87% equity in Tianmai Biotechnology, with a valuation of nearly 8 billion yuan for Tianmai [1] Group 1: Company Actions - China Resources Pharmaceutical's subsidiary has initiated the sale process through the Shanghai United Assets and Equity Exchange, with a starting price of about 1.42 billion yuan [1] - The company currently holds less than 30% equity in Tianmai Biotechnology [1] - The relationship between China Resources Pharmaceutical and Tianmai Biotechnology began in 2016, with an investment made shortly after the company's IPO [2][7] Group 2: Market Context - The insulin market was valued at approximately 19 billion yuan in public medical institutions in 2016, with significant sales from major players [4] - Tianmai Biotechnology has potential in the oral insulin market, which could cater to a large patient base [5] - The company has faced challenges, including delays in product approvals and market competition, particularly with the introduction of national insulin procurement policies [8] Group 3: Financial Performance - China Resources Pharmaceutical's revenue and net profit have been declining, with projected revenues of 246.475 billion yuan, 259.475 billion yuan, and 132.716 billion yuan for 2023, 2024, and the first half of 2025, respectively [10] - The company has been divesting assets to streamline operations, including significant stakes in various subsidiaries [11]

Group 1 - The company is involved in the biopharmaceutical sector, producing products such as active pharmaceutical ingredients, excipients, and pharmaceutical intermediates [2] - The company's products are primarily applied in the field of biomedicine [2] - The company expressed gratitude for investor interest in its biopharmaceutical collaborations [2]

Group 1 - The core point of the article is that Watson Bio is currently in the III phase of clinical research for its nine-valent HPV vaccine and will disclose any substantial and phase-related progress in its vaccine development in a timely manner [2]

（文章来源：北京商报） 特宝生物表示，报告期内，随着公司产品派格宾联合核苷（酸）类似物用于成人慢性乙型肝炎患者的 HBsAg持续清除增加适应症的获批，以及乙肝临床治愈相关科学证据的不断积累，派格宾作为全球首个 以乙肝临床治愈为治疗目标的药物，在慢乙肝临床治愈联合治疗中的基石地位进一步凸显；新产品益佩 生获批上市并纳入《国家基本医疗保险、工伤保险和生育保险药品目录》，凭借安全、有效、便捷的优 势，产品的市场推广工作进展顺利。尽管受新产品上市初期市场拓展、核心产品加大覆盖提升等因素影 响，相关费用有所增加，但公司全力推动创新成果快速进入临床应用，整体经营仍保持稳健增长。 北京商报讯2月10日晚间，特宝生物（688278）发布2025年度业绩快报显示，公司2025年营业收入36.96 亿元，同比增长31.18％；归属净利润10.38亿元，同比增长25.39％。 ...

Core Viewpoint - Watson Bio (300142.SZ) has received approval from the National Medical Products Administration for a clinical trial of its live attenuated varicella vaccine, marking a significant step in its vaccine development efforts [1] Group 1: Clinical Trial Approval - The clinical trial approval notice for the varicella vaccine was issued recently, with the approval number 2026LP00378 [1] - The vaccine is classified as a preventive biological product and is intended for the prevention of chickenpox [1] - The approval confirms that the vaccine meets the registration requirements as per the relevant laws and regulations, allowing clinical trials to commence [1] Group 2: Vaccine Development - The vaccine is developed using a live attenuated strain of the varicella-zoster virus (VZV) and is produced using a freeze-drying process [1] - Upon administration, the vaccine is designed to stimulate the immune system to produce immunity against the varicella-zoster virus, thereby preventing chickenpox [1] - The clinical trials must be conducted within three years from the date of approval, with the notice becoming invalid if no informed consent is obtained from participants within that timeframe [1]

Market Overview - The Hang Seng Index rose by 0.58% to close at 27,183.15 points, while the Hang Seng Tech Index increased by 0.62% to 5,451.03 points, and the National Enterprises Index climbed by 0.81% to 9,242.75 points [1] - The index opened at 27,202.96 points, initially rising before retreating, and ultimately gained 155.99 points with a total turnover exceeding 234 billion HKD [1] - There were 1,344 advancing stocks, 923 declining stocks, and 896 stocks closing flat by midday [1] - The net inflow for the southbound trading (Hong Kong Stock Connect) was 84.7 million HKD [1] Sector Performance - Most sectors experienced gains, including chips, optical communications, biomedicine, new energy vehicles, oil and gas, banking, aviation, and port transportation [1] - Mixed performance was noted in new consumption, non-ferrous metals, and brokerage sectors, while gold, technology, real estate, and electricity sectors mostly declined [1] Individual Stock Movements - Notable stock movements included Pop Mart rising by 4.90%, Longi Green Energy increasing by 8.88%, Xiaomi Group up by 1.08%, and SMIC gaining 1.71% [1] - China Ping An rose by 0.62%, AIA fell by 0.52%, Zijin Mining increased by 2.52%, and Tianzuo Zhixin surged by 12.40% [1] - COSCO Shipping Energy rose by 5.49%, Zhihui gained 14.81%, and Rongchang Biotech increased by 3.64% [1] - HSBC Holdings rose by 0.72%, Industrial and Commercial Bank of China increased by 0.77%, and China Petroleum gained 1.64% [1] Top Traded Stocks - Tencent Holdings saw a decline of 1.61% with a turnover exceeding 16.1 billion HKD; Alibaba rose by 1.65% with a turnover over 9.3 billion HKD; Meituan fell by 2.47% with a turnover of 6.6 billion HKD [2]

Group 1 - The core project "Rapid Confirmation and Precise Prevention and Control of Emerging Viral Infectious Diseases" won the second prize of Jiangsu Province Science and Technology Progress Award, highlighting the company's achievements in technological innovation [1] - The project was led by Jiangsu Provincial Center for Disease Control and Prevention, with the company contributing core technological innovations in the field of inactivated enterovirus vaccines [1] - The project addresses key challenges in the prevention and control of emerging viral infectious diseases, establishing an efficient response system [1] Group 2 - The company has developed bivalent and quadrivalent inactivated enterovirus vaccines (Vero cells), which received clinical trial approval from the National Medical Products Administration in February 2025 [2] - Currently, there are no approved bivalent or quadrivalent enterovirus vaccines available globally, indicating a significant market opportunity for the company [2] - Successful development of these vaccines will enhance the company's multi-valent vaccine portfolio, strengthening its core competitiveness and market position [2]

特宝生物发布业绩快报，2025年度实现营业总收入36.96亿元，同比增长31.18%；净利润10.38亿元，同 比增长25.39%。报告期内，随着公司产品派格宾联合核苷（酸）类似物用于成人慢性乙型肝炎患者的 HBsAg持续清除增加适应症的获批，以及乙肝临床治愈相关科学证据的不断积累，派格宾作为全球首个 以乙肝临床治愈为治疗目标的药物，在慢乙肝临床治愈联合治疗中的基石地位进一步凸显；新产品益佩 生获批上市并纳入《国家基本医疗保险、工伤保险和生育保险药品目录》，凭借安全、有效、便捷的优 势，产品的市场推广工作进展顺利。 ...

Core Viewpoint - Watson Bio has received approval from the National Medical Products Administration for clinical trials of its varicella live attenuated vaccine, developed in collaboration with its subsidiaries [1] Group 1: Vaccine Development - The varicella live attenuated vaccine is developed using a live attenuated strain of the varicella-zoster virus and is produced through a freeze-drying process [1] - The vaccine aims to stimulate the immune system to produce immunity against the varicella-zoster virus for the prevention of chickenpox [1] Group 2: Market Context - Currently, there are six companies in China that have received marketing approval for their varicella live attenuated vaccines [1]

Core Viewpoint - The collaboration between Innovent Biologics and Eli Lilly marks the seventh partnership since 2015, focusing on the global development of innovative drugs in oncology and immunology, showcasing Innovent's strong R&D capabilities recognized by multinational corporations [1] Event - On February 8, Innovent Biologics announced a strategic partnership with Eli Lilly to advance the global development of innovative drugs in oncology and immunology, with Innovent leading the projects from drug discovery to clinical concept validation in China [1] Financial Details - The collaboration includes an upfront payment of $350 million and a total package worth $8.85 billion, with Innovent retaining all rights in Greater China while Eli Lilly obtains exclusive global development and commercialization rights outside this region [1] - Innovent is eligible for up to approximately $8.5 billion in milestone payments related to R&D, regulatory, and commercialization, along with a tiered sales share from net sales outside Greater China [1] R&D Capacity - The partnership indicates high recognition of Innovent's early-stage R&D and concept validation capabilities in oncology and immunology by Eli Lilly, which has a strong portfolio in these areas [2] - Innovent has 17 commercialized drugs, with one product under NMPA review, four new drug molecules in Phase III or critical clinical studies, and 15 additional new drug candidates in clinical research [2] Profit Forecast and Investment Recommendation - Innovent's extensive layout in oncology is expected to enhance revenue and reduce marginal costs, while the company also has competitive products in metabolic, autoimmune, and ophthalmology fields [2] - A global strategic partnership with Takeda, valued at $11.4 billion, is anticipated to accelerate the introduction of next-generation IO and ADC therapies to the global market, marking a significant step in Innovent's internationalization [2] - Revenue projections for Innovent from 2025 to 2027 are estimated at 11.968 billion yuan, 22.804 billion yuan, and 26.572 billion yuan, with net profits of 0.886 billion yuan, 6.679 billion yuan, and 8.004 billion yuan respectively [2] - The company’s reasonable market value is estimated at 232.7 billion HKD, with a target price set at 136.12 HKD, maintaining a "buy" rating [2]